People: Abeona Therapeutics Inc (ABEO.OQ)
18 Sep 2019
Dr. Joao Siffert, M.D., is Chief Executive Officer, Director of the Company. He previously served as the Company’s Interim Chief Executive Officer since November 26, 2018. Dr. Siffert had also served as the Company’s Head of Research and Development and Chief Medical Officer since October 2018. He served as Chief Medical Officer for Ceregene from 2007 to 2011, where he was responsible for clinical development of adeno-associated viral (AAV2)-based gene therapies for Parkinson’s and Alzheimer’s diseases. Dr. Siffert also led the R&D and medical organizations at Avanir Pharmaceuticals from 2011-2016 and Avera Pharmaceuticals from 2005-2007, before most recently guiding translational research, clinical development, regulatory, and medical affairs, and health economics as Chief Scientific and Medical Officer for Nestle Health Science from 2016 until his appoint as Abeona’s Head of Research and Development and Chief Medical Officer in 2018. In 2017, Dr. Siffert was appointed to the board of directors of gene therapy developer AveXis Inc., which was subsequently acquired by Novartis. Dr. Siffert earned his M.D. from the University of São Paulo, Brazil, and holds an M.B.A. from Columbia University. He completed medical residencies in pediatrics at New York University (NYU) School of Medicine and in neurology at Harvard Medical School, followed by a fellowship in neuro-oncology at NYU. The American Board of Neurology and Psychiatry certified Dr. Siffert in 1996.
|Total Annual Compensation,||--|
|Restricted Stock Award,||--|
|Long-Term Incentive Plans,||--|
|Fiscal Year Total,||--|